What is Ever/Body?
Ever/Body operates as a sophisticated skincare service provider, bridging the gap between traditional dermatology and luxury wellness experiences. By offering a curated suite of medical-grade aesthetic treatments and personalized product regimens, the company has established a distinct market position. Its operational framework focuses on delivering consistent, high-quality clinical outcomes in a modern, accessible environment, effectively disrupting the fragmented medical spa landscape through a tech-enabled, consumer-centric approach to dermatological care.
How much funding has Ever/Body raised?
Ever/Body has raised a total of $110.9M across 4 funding rounds:
Series A
$17M
Debt
$401K
Series B
$38M
Series C
$55.5M
Series A (2019): $17M with participation from ACME Capital, Tiger Global Management, Redesign Health, and Declaration Partners
Debt (2021): $401K led by PPP
Series B (2021): $38M supported by Tiger Global Management, Addition, Gaingels, Redesign Health, Declaration Partners, Acme Capital, Fifth Wall, and MetaProp
Series C (2022): $55.5M featuring Declare Capital, Tiger Global Management, and Acme Capital
Key Investors in Ever/Body
Tiger Global Management
Tiger Global Management is an investment firm deploying capital in both public and private markets. The company was founded in 2001 and is headquartered in New York City, New York.
Acme Capital
ACME is a San Francisco based early-stage venture capital firm investing in breakthrough enabling technologies and business model innovations disrupting massive sectors.
Redesign Health
Founded in 2018, Redesign Health is powering a new kind of innovation in healthcare by ideating, building, and scaling solutions to solve the biggest health challenges.
What's next for Ever/Body?
With the infusion of $55.5M, Ever/Body is well-positioned to accelerate its geographic footprint and enhance its proprietary service delivery platform. The company's strategic roadmap likely involves scaling its physical presence across key urban centers while simultaneously investing in digital infrastructure to improve patient retention and personalized care pathways. As the firm transitions from its current growth phase toward broader market dominance, the focus will remain on maintaining clinical excellence while leveraging its robust capital base to navigate the competitive landscape of modern aesthetic medicine.
See full Ever/Body company page
